Ozempic (Sematide)
A GLP-1 receptor agonist used for type 2 diabetes and sometimes prescribed for weight management. It reduces appetite and slows gastric emptying.
- Weekly injection
- Non-surgical treatment
- Requires medical monitoring
Obesity treatment is no longer limited to diet and exercise. Depending on your weight, medical conditions and long-term goals, treatment may include structured lifestyle support, prescription medication or bariatric surgery.
Ozempic and Mounjaro may reduce appetite and support weight loss, while bariatric surgery can provide a more durable option for patients with severe or treatment-resistant obesity. The most appropriate pathway should be selected after a multidisciplinary assessment.
Each treatment works differently and may suit a different patient profile.
A GLP-1 receptor agonist used for type 2 diabetes and sometimes prescribed for weight management. It reduces appetite and slows gastric emptying.
A dual GIP and GLP-1 receptor agonist. Its combined hormonal action may produce greater weight loss than single-pathway GLP-1 treatment in some patients.
A surgical treatment that changes stomach anatomy and metabolic signalling to support substantial, long-term weight loss and improvement in obesity-related disease.
Estimated total body weight loss
Estimated total body weight loss
Estimated total body weight loss
Medication-associated weight loss may be difficult to maintain after treatment is stopped. Surgery generally offers more durable results, but regain may still occur without nutrition, activity and follow-up.
*Reported percentages can vary across different clinical studies, patient populations, treatment durations and individual circumstances. Individual results are not guaranteed.
Review medical history, BMI, obesity-related conditions, previous treatment and personal goals.
Treatment may begin with lifestyle support, prescription medication or bariatric surgery.
Non-surgical care should be reviewed regularly. If sustainable results are not achieved, surgery may be discussed.
Medication can sometimes be used before surgery, after surgery or for weight regain as part of a supervised plan.
Weight regain may occur when GLP-1 medication is stopped.
Nausea, vomiting and other gastrointestinal symptoms can occur.
Surgery carries a 1% risk of complications such as bleeding, leakage, infection and hernia.
Nutrition monitoring and vitamin supplementation may be required.
A consultation is the safest way to determine whether medication, surgery or another approach is suitable for you.
Ozempic is primarily approved for type 2 diabetes. A clinician may discuss semaglutide-based weight-management treatment where medically appropriate.
Mounjaro acts on two hormone pathways and may produce greater average weight loss in some patients, but suitability and response vary.
Regain is possible after medication is stopped, particularly if appetite returns and long-term nutrition and activity changes are not maintained.
Surgery may be considered for patients with higher BMI, obesity-related disease or unsuccessful non-surgical treatment, subject to specialist assessment.
In selected patients, medication can be used before surgery to reduce risk or after surgery to support treatment of inadequate weight loss or regain.
Copyright © 2026 Dosti. All Rights Reserved.